MXPA03001717A - Method for treatment of migraine. - Google Patents

Method for treatment of migraine.

Info

Publication number
MXPA03001717A
MXPA03001717A MXPA03001717A MXPA03001717A MXPA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A MX PA03001717 A MXPA03001717 A MX PA03001717A
Authority
MX
Mexico
Prior art keywords
migraine
treatment
Prior art date
Application number
MXPA03001717A
Other languages
Spanish (es)
Inventor
Hartmut Porst
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of MXPA03001717A publication Critical patent/MXPA03001717A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MXPA03001717A 2000-08-30 2001-08-27 Method for treatment of migraine. MXPA03001717A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22908300P 2000-08-30 2000-08-30
PCT/US2001/026740 WO2002019213A2 (en) 2000-08-30 2001-08-27 Method for treatment of migraine using pde5 inhibitors

Publications (1)

Publication Number Publication Date
MXPA03001717A true MXPA03001717A (en) 2003-09-22

Family

ID=22859786

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001717A MXPA03001717A (en) 2000-08-30 2001-08-27 Method for treatment of migraine.

Country Status (8)

Country Link
EP (1) EP1313478A2 (en)
JP (1) JP2004507514A (en)
CN (1) CN1471397A (en)
AU (1) AU2001286832A1 (en)
BR (1) BR0113644A (en)
CA (1) CA2419623A1 (en)
MX (1) MXPA03001717A (en)
WO (1) WO2002019213A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
DE10325813B4 (en) 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxis and / or therapy in portal hypertension
EP2425819A1 (en) 2007-02-11 2012-03-07 MAP Pharmaceuticals Inc Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US20080260643A1 (en) 2007-03-27 2008-10-23 Omeros Corporation Use of pde7 inhibitors for the treatment of movement disorders
JP2011518881A (en) 2008-04-28 2011-06-30 ゾゲニクス インコーポレーティッド Formulations for the treatment of migraine
US20130323288A1 (en) 2010-07-08 2013-12-05 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
US10010514B2 (en) 2010-07-08 2018-07-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US9532959B2 (en) 2010-07-08 2017-01-03 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US20130040971A1 (en) * 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
US10105330B2 (en) 2012-01-04 2018-10-23 Wellesley Pharmaceuticals, Llc Extended, delayed and immediate release formulation method of manufacturing and use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
KR20190049928A (en) 2012-01-04 2019-05-09 웰즐리 파마슈티컬스 엘엘씨 Delayed-release formulation for reducing the frequency of urination and method of use thereof
KR20150048741A (en) * 2012-07-27 2015-05-07 웰즐리 파마슈티컬스 엘엘씨 Pharmaceutical formulation for reducing frequency of urination and method of use thereof
EP2935280A4 (en) 2012-12-21 2016-05-25 Map Pharmaceuticals Inc 8'-hydroxy-dihydroergotamine compounds and compositions
US10792326B2 (en) 2013-06-28 2020-10-06 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for bedwetting and method of use thereof
JP2017114764A (en) * 2014-04-25 2017-06-29 武田薬品工業株式会社 Migraine therapeutic agent
US10105328B2 (en) 2014-06-06 2018-10-23 Wellesley Pharmaceuticals, Llc Composition for reducing frequency of urination, method of making and use thereof

Also Published As

Publication number Publication date
AU2001286832A1 (en) 2002-03-13
CN1471397A (en) 2004-01-28
CA2419623A1 (en) 2002-03-07
BR0113644A (en) 2003-07-29
EP1313478A2 (en) 2003-05-28
WO2002019213A2 (en) 2002-03-07
JP2004507514A (en) 2004-03-11
WO2002019213A3 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
GB0014969D0 (en) Novel method of treatment
MXPA03001717A (en) Method for treatment of migraine.
ZA200108446B (en) Novel method of treatment.
EP1414464A4 (en) Method for treating glaucoma v
ZA200300418B (en) Method of treating cardiovascular disease.
GB0129976D0 (en) Treatment method
MXPA03003632A (en) Method for treatment of tumors using combination therapy.
EP1465968A4 (en) Methods for treating deodorizer distillate
HK1064261A1 (en) Method for the treatment of tobacco.
EP1581234A4 (en) Methods for treating migraine
ZA200108494B (en) Method of treating cartilage damage.
MXPA02012907A (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity.
MXPA03006607A (en) Combined method for treating hormono-dependent disorders.
AP2004003070A0 (en) The method of treating cancer.
GB0120147D0 (en) Treatment method
EP1389105A4 (en) Method of treatment
MXPA03003347A (en) Method of purifying plavastatin.
MXPA03004017A (en) Method for the treatment of inflammation.
GB0112216D0 (en) Method of treatment
GB0026838D0 (en) Treatment method
GB0118892D0 (en) Method of treatment
AU2001262177A1 (en) Method of treatment
ZA200101058B (en) Process for the treatment of gases.
HUP0105152A3 (en) Method for treatment of headache
ZA200007396B (en) Method of treatment.